NASDAQ:KURA Kura Oncology Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $17.46 +0.11 (+0.63%) (As of 06/28/2022 04:00 PM ET) Add Compare Share Today's Range$16.85▼$17.8250-Day Range$10.71▼$18.1752-Week Range$10.41▼$22.44Volume823,973 shsAverage Volume762,265 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$38.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address KURA Stock Forecast (MarketRank)Overall MarketRank™2.09 out of 5 starsMedical Sector492nd out of 1,436 stocksPharmaceutical Preparations Industry210th out of 687 stocksAnalyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Kura Oncology has a forecasted upside of 117.6% from its current price of $17.46.Amount of Analyst CoverageKura Oncology has received no research coverage in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesKura Oncology has received 377 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKura Oncology has received 169 “underperform” votes. (Add your “underperform” vote.)Community SentimentKura Oncology has received 69.05% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote “Outperform” if you believe KURA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Kura Oncology is held by insiders.Percentage Held by Institutions94.65% of the stock of Kura Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($2.19) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kura Oncology (NASDAQ:KURA)Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.Read More KURA Stock News HeadlinesJune 19, 2022 | americanbankingnews.comReviewing SELLAS Life Sciences Group (NASDAQ:SLS) & Kura Oncology (NASDAQ:KURA)June 15, 2022 | americanbankingnews.comKura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from BrokeragesJune 4, 2022 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Shares Gap Down to $13.58May 4, 2022 | seekingalpha.comKura Oncology Q1 2022 Earnings PreviewMay 4, 2022 | seekingalpha.comKura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | finance.yahoo.comKura Oncology Reports First Quarter 2022 Financial ResultsApril 27, 2022 | finance.yahoo.comKura Oncology to Report First Quarter 2022 Financial ResultsApril 8, 2022 | finance.yahoo.comKura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung CancerMarch 11, 2022 | morningstar.comKura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting | MorningstarMarch 11, 2022 | benzinga.comAdagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022March 8, 2022 | finance.yahoo.comKura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual MeetingFebruary 25, 2022 | benzinga.comCredit Suisse Maintains Outperform on Kura Oncology, Raises Price Target to $27February 24, 2022 | benzinga.comKura Oncology: Q4 Earnings InsightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees121Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/28/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$38.00 High Stock Price Forecast$80.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+117.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.990010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.49% Return on Assets-24.28% Debt Debt-to-Equity RatioN/A Current Ratio27.48 Quick Ratio27.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.61 per share Price / Book2.29Miscellaneous Outstanding Shares66,636,000Free Float63,371,000Market Cap$1.16 billion OptionableOptionable Beta1.40 Kura Oncology Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kura Oncology stock. View analyst ratings for Kura Oncology or view top-rated stocks. What is Kura Oncology's stock price forecast for 2022? 6 equities research analysts have issued 12-month price objectives for Kura Oncology's stock. Their KURA stock forecasts range from $26.00 to $80.00. On average, they expect Kura Oncology's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 117.6% from the stock's current price. View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts. How has Kura Oncology's stock performed in 2022? Kura Oncology's stock was trading at $14.00 at the beginning of 2022. Since then, KURA stock has increased by 24.7% and is now trading at $17.46. View the best growth stocks for 2022 here. When is Kura Oncology's next earnings date? Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Kura Oncology. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same quarter in the prior year, the company earned ($0.46) EPS. View Kura Oncology's earnings history. Who are Kura Oncology's key executives? Kura Oncology's management team includes the following people: Dr. Troy Edward Wilson J.D., Ph.D., Chairman, CEO, Pres & Principal Financial Officer (Age 53, Pay $984.61k)Ms. Kathleen Ford, Chief Operating Officer (Age 75, Pay $689.32k)Dr. Marc Grasso M.D., Advisor (Age 48, Pay $651.68k)Ms. Kirsten Flowers, Chief Commercial Officer (Age 47, Pay $642.98k)Dr. Stephen Dale M.D., Chief Medical Officer (Age 50, Pay $811.58k)Mr. Thomas Doyle, Principal Accounting Officer & Sr. VP of Fin. and Accounting (Age 51)Mr. Pete De Spain, Sr. VP of Investor Relations & Corp. CommunicationsMs. Teresa Brophy Bair Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 51)Mr. James E. Basta J.D., Esq., Chief Compliance Officer & Corp. Sec. (Age 56)Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing Who are some of Kura Oncology's key competitors? Some companies that are related to Kura Oncology include Hypera (HYPMY), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Cytokinetics (CYTK), Cerevel Therapeutics (CERE), Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Karuna Therapeutics (KRTX), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Bausch Health Companies (BHC), Blueprint Medicines (BPMC), Harmony Biosciences (HRMY) and Amicus Therapeutics (FOLD). View all of KURA's competitors. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.42%), Deerfield Management Company L.P. Series C (6.63%), Suvretta Capital Management LLC (5.84%), Deep Track Capital LP (5.12%), Vanguard Group Inc. (5.00%) and State Street Corp (4.95%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Kathleen Ford, Marc Grasso and Troy Edward Wilson. View institutional ownership trends for Kura Oncology. Which major investors are selling Kura Oncology stock? KURA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Wellington Management Group LLP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., State Street Corp, SG Americas Securities LLC, and Bank of America Corp DE. Company insiders that have sold Kura Oncology company stock in the last two years include Kathleen Ford, Marc Grasso, and Troy Edward Wilson. View insider buying and selling activity for Kura Oncology or view top insider-selling stocks. Which major investors are buying Kura Oncology stock? KURA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Deerfield Management Company L.P. Series C, Deep Track Capital LP, Aaron Wealth Advisors LLC, Eventide Asset Management LLC, Verition Fund Management LLC, Verition Fund Management LLC, and Affinity Asset Advisors LLC. View insider buying and selling activity for Kura Oncology or or view top insider-buying stocks. How do I buy shares of Kura Oncology? Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $17.46. How much money does Kura Oncology make? Kura Oncology (NASDAQ:KURA) has a market capitalization of $1.16 billion. The company earns $-130.47 million in net income (profit) each year or ($1.990010) on an earnings per share basis. How many employees does Kura Oncology have? Kura Oncology employs 121 workers across the globe. How can I contact Kura Oncology? Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for Kura Oncology is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at [email protected]. This page (NASDAQ:KURA) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
